Clinical Trials Logo

Clinical Trial Summary

Esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses. This study hypothesized that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients.


Clinical Trial Description

Single subanaesthetic doses of i.v. esketamine may significantly improve symptoms in psychiatric patients with major depression. In patients undergoing cardiac surgery, postoperative depressive symptoms are common. This study hypothesizes that low-dose esketamine has a preventive effect on postoperative depression. However, evidence in this aspect is insufficient. The purpose of this study is to investigate the effect of a subanaesthetic dose of ketamine on POD for patients undergoing cardiac surgery. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05155969
Study type Interventional
Source Beijing Chao Yang Hospital
Contact Anshi Wu Wu, Ph.D
Phone +861085351330
Email wuanshi1965@163.com
Status Recruiting
Phase N/A
Start date December 1, 2021
Completion date December 15, 2022

See also
  Status Clinical Trial Phase
Completed NCT02452060 - Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy Phase 2/Phase 3
Recruiting NCT05625360 - REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss Phase 3
Completed NCT05233566 - Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial Phase 3